Breast cancer metastasis: Markers and Models

Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nature reviews. Cancer (Impact Factor: 37.4). 09/2005; 5(8):591-602. DOI: 10.1038/nrc1670
Source: PubMed


Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant organs. At primary diagnosis, prognostic markers are used to assess whether the transition to systemic disease is likely to have occurred. The prevailing model of metastasis reflects this view--it suggests that metastatic capacity is a late, acquired event in tumorigenesis. Others have proposed the idea that breast cancer is intrinsically a systemic disease. New molecular technologies, such as DNA microarrays, support the idea that metastatic capacity might be an inherent feature of breast tumours. These data have important implications for prognosis prediction and our understanding of metastasis.

Download full-text


Available from: Laura J van 't Veer, Aug 11, 2015
46 Reads
  • Source
    • "Invasion and angiogenesis are key steps of the metastatic process of breast cancer [2] [11]. Vascular endothelial growth factor (VEGF) [12] [13] and platelet-derived growth factor-C (PDGF-C) [14] [15] are important mediators of angiogenesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is one of the most common malignant diseases in women. The main cause of death from breast cancer is its metastases at distant sites in the body. Interleukin-33 (IL-33) is a cytokine of the IL-1 family and found overexpressed in various cancers. The aim of the present study was to explore the association of serum IL-33 and sST2 with breast cancer. Here, the serum levels of Interleukin-33 (IL-33) and sST2 were found significantly higher in breast cancer patients than in healthy volunteers. Serum levels of vascular endothelial growth factor (VEGF), metalloproteinase-11 (MMP-11), and platelet-derived growth factor-C (PDGF-C) were also greater in breast cancer patients compared to healthy volunteers. We found that serum levels of IL-33 or sST2 were positively correlated with the serum levels of VEGF, MMP-11, and PDGF-C. Moreover, breast cancer dataset downloaded from The Cancer Genome Atlas showed that patients with higher level of MMP-11 or PDGF-C expression had shorter survival time than those with lower level of these proteins. In conclusion, IL-33 and sST2 may serve as noninvasive diagnosis markers for breast cancer. IL-33 and sST2 were significantly associated with MMP-11 or PDGF-C which indicated poor prognosis of breast cancer patients.
    Disease markers 10/2015; 2015(5):516895. DOI:10.1155/2015/516895 · 1.56 Impact Factor
  • Source
    • "A word of caution should be spent about the fact that the event considered in the INT case series was the occurrence of distant metastases, whereas only disease-specific death was available in the METABRIC data set. It is well known that the main cause of death for breast cancer is the development of metastasis at distant sites, rather than the primary tumor (Weigelt et al, 2005), which justifies our analyses in the second cohort. However, it should be noted that also patients untreated after surgery were likely to have received several treatments after relapse and before dying, and no information is available on this aspect. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer clinical outcome is affected by tumor molecular features, and the identification of subtype-specific prognostic biomarkers is relevant for breast cancer translational research. Gene expression signatures proved to be able to complement prognostic information provided by classical clinico-pathological features. Recently, microRNAs (miRNAs) have been causally linked to tumorigenesis and cancer progression and have been associated with patient outcome, also in breast cancer. MicroRNAs associated with the development of distant metastasis were identified in a cohort of 92 ESR1+/ERBB2- lymph node-negative breast cancers from patients not receiving adjuvant treatment. Results were confirmed and further investigated in a total of 1246 miRNA and gene expression profiles of the Molecular Taxonomy of Breast Cancer International Consortium data set. Moderated t-test, univariable and multivariable Cox regression models were used for statistical analyses. miR-30e* was identified as independent protective prognostic factor in lymph node-negative untreated patients with ESR1+/ERBB2- tumours and retained a significant association with a good prognosis in treated patients with the same tumor subtype as well as in the ERBB2+ subtype, but not in ESR1-/ERBB2- tumours. We highlighted a relevant and subtype-specific role in breast cancer for miR-30e* and demonstrated that adding miRNA markers to gene signatures and clinico-pathological features can help for a better prognostication.British Journal of Cancer advance online publication, 9 June 2015; doi:10.1038/bjc.2015.206
    British Journal of Cancer 06/2015; 113(2). DOI:10.1038/bjc.2015.206 · 4.84 Impact Factor
  • Source
    • "The main cause of death in these patients was its metastases at distant sites. Owing to difficulty in predicting metathesis development many women are over-treated and suffer toxic side effects of chemotherapy (Weigelt et al., 2005). Recent epidemiological studies suggested the presence of an inverse association between regular intake of NSAIDs and the relative risk of breast cancer (Harris et al., 2005; Harris et al., 1995; Harris et al., 1996). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The study was devised to investigate the effect of retinoic acid trifloromethyl chalcone (RAFC) on mammary carcinogenesis in female rats. The data revealed a significant decrease in number of rats with mammary tumor, number of tumors per rat and tumor volume by 54, 72 and 75% respectively in RAFC group compared to control group. The ibuprofen treated rats also showed a significant decrease in number of rats with tumor, number of tumors per rat and tumor volumes by 43%, 55%, and 59%, respectively. Treatment of rats with RAFC also increased the latency period of tumor induction significantly. Median detection period (50% of tumors) was 92, 83 and 56 days respectively in the rats from RAFC, ibuprofen and control groups respectively after DMBA induction. These results demonstrate that RAFC possesses strong chemopreventive activity against mammary carcinogenesis. © 2015, Bangladesh Pharmacological Society. All right reserved.
    Bangladesh Journal of Pharmacology 03/2015; 10(1). DOI:10.3329/bjp.v10i1.21599 · 1.05 Impact Factor
Show more